These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8700521)

  • 1. Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs.
    Rodenhiser D; Chakraborty P; Andrews J; Ainsworth P; Mancini D; Lopes E; Singh S
    Oncogene; 1996 Jun; 12(12):2623-9. PubMed ID: 8700521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the neurofibromatosis type 1 (NF1) tumour-suppressor gene.
    Rodenhiser DI; Andrews JD; Mancini DN; Jung JH; Singh SM
    Mutat Res; 1997 Feb; 373(2):185-95. PubMed ID: 9042399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes.
    Cheung LW; Lee YF; Ng TW; Ching WK; Khoo US; Ng MK; Wong AS
    FEBS Lett; 2007 Oct; 581(24):4668-74. PubMed ID: 17826769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
    Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
    Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
    Preisler-Adams S; Schönbuchner I; Fiebig B; Welling B; Dworniczak B; Weber BH
    Cancer Genet Cytogenet; 2006 Jul; 168(1):44-9. PubMed ID: 16772120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
    Gayther SA; Mangion J; Russell P; Seal S; Barfoot R; Ponder BA; Stratton MR; Easton D
    Nat Genet; 1997 Jan; 15(1):103-5. PubMed ID: 8988179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
    Mancini DN; Rodenhiser DI; Ainsworth PJ; O'Malley FP; Singh SM; Xing W; Archer TK
    Oncogene; 1998 Mar; 16(9):1161-9. PubMed ID: 9528858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large majority of single-nucleotide mutations along the dystrophin gene can be explained by more than one mechanism of mutagenesis.
    Todorova A; Danieli GA
    Hum Mutat; 1997; 9(6):537-47. PubMed ID: 9195228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
    Shih HA; Nathanson KL; Seal S; Collins N; Stratton MR; Rebbeck TR; Weber BL
    Clin Cancer Res; 2000 Nov; 6(11):4259-64. PubMed ID: 11106241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
    Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
    Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.
    Petrij-Bosch A; Peelen T; van Vliet M; van Eijk R; Olmer R; Drüsedau M; Hogervorst FB; Hageman S; Arts PJ; Ligtenberg MJ; Meijers-Heijboer H; Klijn JG; Vasen HF; Cornelisse CJ; van 't Veer LJ; Bakker E; van Ommen GJ; Devilee P
    Nat Genet; 1997 Nov; 17(3):341-5. PubMed ID: 9354803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of CpG methylation in the BRCA1 promoter region.
    DiNardo DN; Butcher DT; Robinson DP; Archer TK; Rodenhiser DI
    Oncogene; 2001 Aug; 20(38):5331-40. PubMed ID: 11536045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.